Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Kidney Int. 2024 Aug;106(2):183-185. doi: 10.1016/j.kint.2024.05.016.
Persistent enhancement of glycolysis in kidney tubular epithelial cells has been linked to the progression of chronic kidney disease, although the underlying mechanisms are largely unknown. In this issue of Kidney International, Wang et al. report that the glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 plays a crucial role in kidney fibrosis by enhancing histone H4 lysine 12 lactylation through lactate accumulation. This increases the transcription of nuclear factor-κB-related genes and promotes inflammation and fibrosis. Inhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 reduces these effects, indicating therapeutic potential for kidney fibrosis.
肾管状上皮细胞中糖酵解的持续增强与慢性肾脏病的进展有关,但其中的潜在机制在很大程度上尚不清楚。在本期《国际肾脏》杂志中,Wang 等人报道称,糖酵解酶 6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶 3 通过积累的乳酸促进组蛋白 H4 赖氨酸 12 乳酸化,从而在肾纤维化中发挥关键作用。这会增加核因子-κB 相关基因的转录,并促进炎症和纤维化。抑制 6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶 3 可减少这些作用,表明其对肾纤维化具有治疗潜力。